Roessler N, Miszczyk M, Miyajima K, Dematteis A, Alfarhan AR, Cormio A, Alqahtani AS, Fazekas T, Schuettfort VM, Vetterlein MW, Hu Y, Kasivisvanathan V, Zamboglou C, Leapman MS, Fisch M, Eckstein M, Amin MB, Cacciamani GE, Cheng L, Karakiewicz PI, Rajwa P, Shariat SF. Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review. Eur Urol Focus. 2025 Dec 17:S2405-4569(25)00362-1. doi: 10.1016/j.euf.2025.12.007. Epub ahead of print. PMID: 41412890.
We aimed to synthesize current evidence regarding their prognostic and predictive utility in urologic cancers.
__________
Rahman S, Arun AS, Kim IY, Oh WK, Kim JW, Kim WJ. Navigating the Winding Road Toward Precision Prostate Cancer Care. Gene. 2026 Mar 20;984:149966. doi: 10.1016/j.gene.2025.149966. Epub 2025 Dec 17. PMID: 41419150.
We discuss how Artificial Intelligence/Machine Learning (AI/ML) tools may facilitate the development of near-patient preclinical models of prostate cancer to better capture key aspects of tumor biology.
__________
Diaz GM, Sivanesan N, Strachan S, Sohoni N, DuBois J, Zhao X, Sprenkle PC, Leapman MS. Sociodemographic Factors Associated With Tissue-based Genomic Testing for Prostate Cancer. Urology. 2025 Dec 16:S0090-4295(25)01357-3. doi: 10.1016/j.urology.2025.12.004. Epub ahead of print. PMID: 41412501.
We conducted a retrospective study to identify patients who were diagnosed with localized PCa from 2012-2022 and received genomic testing.
__________
Smani S, Sohoni N, Lacy G, Kong V, Rahman SN, Hayden CS, Gardezi M, Jalfon M, Kellner DS. Implementing HoLEP without fellowship training: A stepwise learning curve from a single surgeon's first 200 cases. Can Urol Assoc J. 2025 Dec 15. doi: 10.5489/cuaj.9351. Epub ahead of print. PMID: 41406344.
In this research letter, we describe the implementation of a HoLEP program by a single, non-fellowship-trained urologist at an academic center.
__________
Zhang H, Chappidi M, Sayar E, Richards H, Chen Z, Liu L, Wadia R, Humphrey PA, Ghali F, Contreras-Sanz A, Black P, Wright J, Harmon S, Haffner M. DA-SSL: Self-supervised domain adaptor to leverage foundational models in TURBT histopathology slides. arXiv [Preprint]. 2025 Dec 15:arXiv:2512.13600 [cs.CV]. Available from: https://arxiv.org/abs/2512.13600. doi:10.48550/arXiv.2512.13600.
Pathology foundational models (PFMs) exhibit limitations on certain cancer or specimen types due to domain shifts - these cancer types were rarely used for pretraining or specimens contain tissue-based artifacts rarely seen within the pretraining population. Such is the case for transurethral resection of bladder tumor (TURBT), which are essential for diagnosing muscle-invasive bladder cancer (MIBC), but contain fragmented tissue chips and electrocautery artifacts and were not widely used in publicly available PFMs. To address this, we propose a simple yet effective domain-adaptive self-supervised adaptor (DA-SSL) that realigns pretrained PFM features to the TURBT domain without fine-tuning the foundational model itself.
__________
Shinder BM, Lee YS, Mao N, Salsabeel N, Zhang Z, Kaur H, Chen X, Chang Q, de Stanchina E, Gopalan A, Sawyers CL, Carver BS. Targeting tumor microenvironment-derived NRG1-HER2/3 signaling with zenocutuzumab restores sensitivity to AR inhibition in PTEN wild-type prostate cancer. Mol Cancer Ther. 2025 Dec 11. doi: 10.1158/1535-7163.MCT-25-0505. Epub ahead of print. PMID: 41379983.
These findings highlight the critical molecular context in which tumor microenvironment (TME)-derived NRG1 impacts responsiveness to AR inhibition and suggest that targeting NRG1 is a promising strategy for overcoming resistance to androgen blockade in PTEN-wildtype prostate cancers.
__________
Schlegel PN, Clark JY, Coward RM, Hirshberg SJ, Honig S, Hsiao W, Kirkby E, Labrecque M, Lee R, Stack J, Tanrikut C, Tiffany P, Treadwell JR, Vij SC, Mehta A. Fertility Restoration After Vasectomy: AUA Guideline Part II. J Urol. 2025 Dec 9:101097JU0000000000004862. doi: 10.1097/JU.0000000000004862. Epub ahead of print. PMID: 41363407.
This Guideline aims to provide a contemporary overview of options for future fertility following vasectomy.
__________
Schlegel PN, Clark JY, Coward RM, Hirshberg SJ, Honig S, Hsiao W, Kirkby E, Labrecque M, Lee R, Stack J, Tanrikut C, Tiffany P, Treadwell JR, Vij SC, Mehta A. Vasectomy: AUA Guideline Part I. J Urol. 2025 Dec 9:101097JU0000000000004861. doi: 10.1097/JU.0000000000004861. Epub ahead of print. PMID: 41363403.
This Guideline provides a contemporary overview of vasectomy, including a discussion of indications, pre-operative counseling and preparation, peri-operative considerations, procedural techniques, potential risks and complications, and post-operative care to ensure that healthcare providers offer accurate, evidence-based information to patients considering this method of permanent contraception.
__________
Chang JC, Perez-Londoño A, Kaul S, Almohtasib J, Fleishman A, Korets R, Chang P, Wagner A, Bellmunt J, Olumi AF, Gershman B. Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis. Urol Oncol. 2026 Feb;44(2):119.e7-119.e16. doi: 10.1016/j.urolonc.2025.11.005. Epub 2025 Dec 9. PMID: 41372083.
We examined the conditional survival free of recurrence and progression in older adults with NMIBC to develop a dynamic risk prediction model.
__________
Rabil Ml, Cahill E, Honig S, (383) It Comes at Night: Early 1900s Stigma on Nocturnal Emissions and Comparison to Current Views, The Journal of Sexual Medicine, Volume 22, Issue Supplement_4, November 2025, qdaf320.378, https://doi.org/10.1093/jsxmed/qdaf320.378
Characterize the sexual culture views on nocturnal seminal emissions in the early 1900s and compare and contrast that to the views of the modern era as it relates to destigmatization of sexual health.
__________
Cahill EM, Huwe V, Bernie H, Brock G, Shindel A, Hellstrom W, Jenkins L, Amarasekera C, Bennett N, Levine L, Yap T, Flores J, Nelson C, Honig S, Mulhall J. (227) Concept Development for a Novel Peyronie’s Disease Questionnaire for Men Who Have Sex With Men. J Sex Med. 2025 Nov;22(Suppl 4):qdaf320.224. doi:10.1093/jsxmed/qdaf320.224.
Our aims are (1) to convene a panel of PD experts to identify potential areas of concern unique to the MSM population with PD, (2) to understand the impact of PD on sexual health, quality of life, and relationship satisfaction in the MSM population using qualitative interviews, and (3) to develop a novel questionnaire for validation focusing on patient concerns and PD attributes in the MSM population.
__________
Cahill EM, Shin D, Honig S. (213) The Fate of Sexual Medicine Abstracts: Quantifying Publication Rates and Time to Publication for Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting. J Sex Med. 2025 Nov;22(Suppl 4):qdaf320.210. doi:10.1093/jsxmed/qdaf320.210.
The objective of this study was to determine the overall publication rate among these abstracts as well as predictors of publication.
__________
Cahill EM, Choksi AU, Rotker K, Honig SC. The impact of the "bent carrot": Google search trends on Peyronie's disease increased following the introduction of collagenase clostridium histolyticum advertisement campaign. J Sex Med. 2026 Jan 7;23(2):qdag004. doi: 10.1093/jsxmed/qdag004. PMID: 41563058.
We aimed to assess the impact of this advertisement campaign by examining public interest in Peyronie’s Disease before and after its release, according to internet search patterns from a major search engine.
__________
Cahill EM, Nolte D, Morrison JC, Andino JJ, Smith JF, Honig SC, Rotker K. (429) Testosterone Use and Semen Quality in a Large Cohort of Men Seeking Fertility Evaluation. The Journal of Sexual Medicine, 22(Supplement_4): qdaf320.423. Published 09 December 2025. doi:10.1093/jsxmed/qdaf320.423.
Using data collected from the Fellow Health mail-in semen analysis (FSA) system, we sought to analyze the rate of testosterone usage for patients seeking fertility evaluation, associated semen quality, and potential predictors of low total motile count (TMC).
__________
Olawoyin O, Choksi AU, Press BH, Sohoni N, Weiss RM, Arlen AM. Ultrasound Diagnostic Features and Management of Torsion-Detorsion. Urology. 2025 Dec 4:S0090-4295(25)01340-8. doi: 10.1016/j.urology.2025.11.254. Epub ahead of print. PMID: 41352377.
To identify ultrasound predictors of those at risk of testicular loss in patients who underwent immediate scrotal exploration in the setting of torsion-detorsion (TDS) diagnosis.
__________
Jackson K, Harnisch B, Honig SC. Compliance With Post Vasectomy Semen Analysis: Comparison of In Office Fresh Testing With Scheduled Office Visit vs. Fresh Laboratory Drop Off Alone. Fertility and Sterility. 2025;124(6S):e236-e237. doi:10.1016/j.fertnstert.2025.07.748.
The aim of this study was to determine whether fresh office-based microscopy with in-person visit or fresh lab-based test with follow-up provider phone call offered the best PVSA compliance rates in our practice.
__________
Heckscher D, Sterling J. VideoKiosk_24 - Robotic Posterior Urethroplasty after Pelvic Fracture Urethral Injury. Urology. 2025;206(Suppl):86. doi:10.1016/j.urology.2025.11.210.
Describe a completely robotic, single-incision approach to posterior urethroplasty, without violating peritoneum and without a perineal incision, that can be performed with a patient supine.
__________
Kaldany A, Cedars B, Nahhas N, Sterling J, Nikolavsky D. Video_01 - Dorsal Onlay Buccal Mucosa Graft Urethroplasty for VUAS After Radiation and Prostatectomy. Urology. 2025;206(Suppl):75-76. doi:10.1016/j.urology.2025.11.177.
We propose that the augmented buccal mucosal graft (MBG) urethroplasty technique can be used safely and effectively in radiated post-prostatectomy fields.
__________
Forman R, Westvold SJ, Long JB, Fan J, Hyslop T, Conlin K, Jacobson S, Wang SY, Leapman MS, Cecchini M, Leeds I, Spees L, Presley C, Yasin F, Taylor M, Kwaramba T, Gross CP, Oeffinger K, Dinan MA. Personalized risk assessment of frailty in long-term cancer survivors. J Geriatr Oncol. 2026 Jan;17(1):102804. doi: 10.1016/j.jgo.2025.102804. Epub 2025 Nov 29. PMID: 41319472.
The objective of this study was to develop a risk stratification tool to identify long-term survivors at the highest risk of becoming frail 5-10 years after cancer diagnosis.
__________
Cheng S, Jin X, Qian J, Jiang Y, Kim IY, Deng S, Mu P. ATHENA: A deep learning-based AI for functional prediction of genomic mutations and synergistic vulnerabilities in prostate cancer. bioRxiv [Preprint]. 2025 Nov 29:2025.11.26.690813. doi: 10.1101/2025.11.26.690813. PMID: 41357974; PMCID: PMC12676378.
We developed ATHENA (Attention-based Therapeutic Network Analyzer), a deep learning-based AI framework that predicts the functional impact of genomic mutations and reveals their synergistic vulnerabilities.
__________
Jiang Y, Cheng S, Zhang CY, Jin X, Li L, Fraidenburg M, Wang C, Kim IY, Mu P. Graded Notch Signaling Functions as a Rheostat of Lineage Plasticity and Therapy Resistance in Prostate Cancer. bioRxiv [Preprint]. 2025 Nov 26:2025.11.23.690056. doi: 10.1101/2025.11.23.690056. PMID: 41394651; PMCID: PMC12699464.
Here, we identify Notch signaling as a graded Rheostat that governs prostate cancer cell fate transitions. Integrative transcriptomic and functional analyses revealed that intermediate Notch activity maintains a stem-like progenitor state, whereas reduced or elevated signaling drives divergent differentiation trajectories toward luminal or neuroendocrine lineages, respectively.
__________
Lim DH, Cavallo JA, Leapman MS, Ghodoussipour S, Kim IY. Comprehensive Outcome Analysis of Single-Port Robot-Assisted Radical Prostatectomy. J Endourol. 2025 Nov 26. doi: 10.1177/08927790251400364. Epub ahead of print. PMID: 41314953.
We compared the perioperative and functional outcomes of SP vs MP RARP performed by a single high-volume robotic surgeon, assessing the efficacy of SP RARP in an academic setting.
__________
Perez-Londoño A, Kaul S, Fleishman A, Korets R, Rayala H, Chang P, Wagner A, Bellmunt J, Olumi AF, Gershman B. Contemporary outcomes and disease burden of high-grade T1 bladder cancer. Can Urol Assoc J. 2025 Nov 25. doi: 10.5489/cuaj.9329. Epub ahead of print. PMID: 41406330.
We examined the contemporary outcomes of HGT1 bladder cancer to inform patient counseling, management, and clinical trial design.
__________
Taylor M, Westvold SJ, Long JB, Hyslop T, Silber A, Forman R, Yasin F, Kwaramba T, Wang SY, Leapman MS, Cecchini M, Leeds I, Spees L, Wheeler SB, Gross CP, Oeffinger K, Dinan MA. Risk of Late-Onset Depression in Long-Term Survivors of Breast, Prostate, and Colorectal Cancer. JAMA Netw Open. 2025 Nov 3;8(11):e2544812. doi: 10.1001/jamanetworkopen.2025.44812. PMID: 41296485; PMCID: PMC12658655.
Identified the risk factors associated with late-onset depression in long-term (5-year) survivors of breast, prostate, or colorectal cancer.
__________
Zhang J, Fontaine K, Volpi T, Zeng T, Du Y, Sun C, Lu Y, Toyonaga T, Onofrey JA, Carson RE. Cranberry: Combined rigid and nonrigid event-by-event motion correction at Yale. In: 2025 IEEE Nuclear Science Symposium (NSS), Medical Imaging Conference (MIC) and Room Temperature Semiconductor Detector Conference (RTSD). 2025 Nov 1-8; p. 1-1. doi: 10.1109/NSS/MIC/RTSD57106.2025.11286359.
The research introduces CRANBERRY, a novel motion-correction framework designed for the NeuroEXPLORER brain PET system, which combines rigid and non-rigid motion correction in an event-by-event manner. Initial tests indicate that CRANBERRY enhances quantification and image quality in non-rigid areas while ensuring effective motion correction in the brain.
__________
Mitchell AP, Salner A, Palyca P, Farooki A, Persaud S, Chakraborty N, Bhamidipati D, Klimchuk M, Dinan MA, Leapman MS, Lipitz-Snyderman A, Hamid A, Ostroff JS, Morris MJ. Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer. JCO Oncol Pract. 2025 Nov 3:OP2500457. doi: 10.1200/OP-25-00457. Epub ahead of print. PMID: 41183247; PMCID: PMC12614842.
We conducted a multicenter, retrospective, cohort study of patients diagnosed with prostate cancer and bone metastases during 2020-2021. The sample included three health systems in the Northeastern United States: two community-based networks and one academic cancer center.
__________
Pavlovich C, Meng X, Kella N, Sonn G, Mynderse L, Michel K, Sprenkle P, Anttinen M, Inman B, Klotz L. Essai controlé randomisé comparant l'ablation par ultrasons transurétrale guidée par IRM à la prostatectomie radicale: résultats périopératoires. Prog Urol FMC. 2025;35(7 Suppl):S16. doi:10.1016/j.pfurol.2025.07.024.
Ablative therapies for prostate cancer (CaP) offer promising efficacy and functional results compared to prostatectomy, but there is a lack of randomized multicenter data. The CAPTAIN study (NCT05027477), comparing TULSA (transurethral ultrasound ablation guided by MRI) to robot-assisted prostatectomy (RP) for intermediate-risk CaP, is the first to achieve its recruitment goal. Here, we present the baseline demographics and initial perioperative outcomes.
__________
Suleja A, Miszczyk M, Sohoni N, Smani S, Souza F, Rajwa P, Leapman M, Shariat SF. 231P Do large language models (LLMs) improve decision-making in clinical practice? A systematic review and meta-analysis. ESMO Real World Data and Digital Oncology. 2025;10(Suppl):100427. doi:10.1016/j.esmorw.2025.100427.
This systematic review and meta-analysis aimed to synthesize the available evidence on clinical decision-making, directly comparing large language models with physicians.
__________
Diaz GM, Webb LT, Lokeshwar SD, Choksi AU, Leapman MS, Sprenkle PC. Initial pain score during viscous lidocaine instillation and clinical characteristics as predictors of overall pain in fusion prostate biopsy. J Biol Methods. 2025 Oct 27;12(4):e99010077. doi: 10.14440/jbm.0230. PMID: 41415884; PMCID: PMC12709519.
This study aimed to identify factors associated with pain during fusion prostate biopsy to optimize the experience of prostate cancer diagnosis and monitoring.
__________
Zhang A, Sivanesan N, Sprenkle PC. Pretreatment Predictors of Pathologic Failure at 1 year After Focal Therapy for Localized Prostate Cancer. Eur Urol Oncol. 2025 Dec;8(6):1710-1711. doi: 10.1016/j.euo.2025.10.004. Epub 2025 Oct 24. PMID: 41136310.
We evaluated pretreatment risk factors, including clinical, imaging, and genomic variables, for predicting pathologic failure on biopsy at 1 yr after FT.
__________
Sivanesan N, Diaz GM, Tan WS, Arora S, Sprenkle PC. Comparative Analysis of Prostate Imaging Reporting and Data System and Prostate Imaging After Focal Ablation Scoring Systems in the Postfocal Therapy Assessment of Clinically Significant Prostate Cancer. Urol Pract. 2026 Jan;13(1):11-12. doi: 10.1097/UPJ.0000000000000899. Epub 2025 Oct 15. PMID: 40986434.
We performed a retrospective review to analyze 59 patients who underwent FT (cryotherapy, TULSA, NanoKnife) at our institution between 2014 and 2024, all of whom obtained posttreatment multiparametric MRI (mpMRI) and targeted + systematic biopsy at 1-year post treatment.
__________
Cai Z, Zeng T, Zhang J, Lieffrig EV, Fontaine K, You C, Revilla EM, Duncan JS, Xin J, Lu Y, Onofrey JA. PET Head Motion Estimation Using Supervised Deep Learning with Attention. IEEE Trans Med Imaging. 2025 Oct 13;PP. doi: 10.1109/TMI.2025.3620714. Epub ahead of print. PMID: 41082441.
We propose a deep-learning head motion correction approach with cross-attention (DL-HMC++) to predict rigid head motion from one-second 3D PET raw data. DL-HMC++ is trained in a supervised manner by leveraging existing dynamic PET scans with gold-standard motion measurements from external hardware-based motion tracking.
__________
Kirsch AJ, Press BH, Arlen AM. Endoscopic treatment for complex cases of vesicoureteral reflux. In: Puri P, Yamataka A, editors. Vesicoureteral reflux. Cham: Springer; 2025. p. [279-285 doi:10.1007/978-3-031-95091-9_17.
While resolution rates may be lower complex cases when compared to primary VUR, more contemporary evidence suggests that the success rates are high enough to support the use of endoscopic injection in the management of VUR in this patient population.
__________
Kirsch AJ, Press BH, Arlen AM. Duplex System and Vesicoureteral Reflux. In: Puri P, Yamataka A, editors. Vesicoureteral Reflux. Cham: Springer; 2025. p. [349-357]. doi:10.1007/978-3-031-95091-9_22.
This chapter will focus on the management of vesicoureteral reflux in the setting of complete ureteral duplication.
__________
Cai Z, Zeng T, Zhang J, Lieffrig EV, Fontaine K, You C, Revilla EM, Duncan JS, Xin J, Lu Y, Onofrey JA. PET Head Motion Estimation Using Supervised Deep Learning with Attention. IEEE Trans Med Imaging. 2025 Oct 13;PP. doi: 10.1109/TMI.2025.3620714. Epub ahead of print. PMID: 41082441.
Hardware-based motion tracking (HMT) has limited applicability in real-world clinical practice. To overcome this limitation, we propose a deep-learning head motion correction approach with cross-attention (DL-HMC++) to predict rigid head motion from one-second 3D PET raw data.
__________
Westvold SJ, Long JB, Fan J, Kc M, Hyslop T, Conlin K, Jacobson S, Silber A, Wang SY, Leapman MS, Leeds I, Spees L, Wheeler SB, Gross CP, Oeffinger K, Dinan MA. Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer. J Natl Cancer Inst. 2026 Jan 1;118(1):130-140. doi: 10.1093/jnci/djaf243. PMID: 41069232.
Cardiovascular disease (CVD) is the leading cause of noncancer mortality in long-term cancer survivors. Population-level assessment of cancer-related exposures is limited with respect to long-term cardiovascular risk in older survivors who have additional aging-related risks.
__________
Jiang Y, Cheng S, Zhang CY, Jin X, Xu Y, Kim IY, Mu P. RUNX1T1-HDAC Reprogramming of the HOX Code Signaling Drives a Targetable Pan-Cancer Lineage Plasticity. bioRxiv [Preprint]. 2025 Oct 8:2025.10.07.681000. doi: 10.1101/2025.10.07.681000. PMID: 41280130; PMCID: PMC12632384.
By analyzing multi-omics data, including 39 HOX genes from over 80,000 RNA-seq samples across 114 cancer types, we discovered that HOX code expression robustly represents cancer cell lineages and reveals multiple previously unrecognized lineage-plastic subtypes in prostate cancer, lung cancer, and acute myeloid leukemia (AML), each displaying altered HOX patterns compared to non-plastic subtypes.
__________
Palencia PS, Rabil M, Jafflon M, Heckscher D, Richmond R, Kong V, Golos A, Chess A, Leapman M, Cavallo J. Automated abstraction algorithm for radical cystectomy surgical outcomes and pathology results. JCO Oncol Pract. 2025 Oct 7;21(10 Suppl):609. doi: 10.1200/OP.2025.21.10_suppl.609.
We hypothesized that a novel electronic medical record (EMR)-based automated algorithm for surgical outcomes and quality metrics following radical cystectomy would demonstrate >90% sensitivity and specificity with significant inter-rater reliability (IRR) with institutional National Surgical Quality Improvement Program (NSQIP) data abstraction.
__________
Palencia PS, Xi X, Zhao X, Smani S, Sivanesan N, Diaz GM, Miszczyk M, Fazekas T, Rajwa P, Cavallo J, Aneja S, An Y, Kim IY, Leapman M. Association between perirectal spacer use and complications following prostate radiation therapy: Results of a national real-world data analysis. JCO Oncol Pract. 2025 Oct 7;21(10 Suppl):571. doi:10.1200/OP.2025.21.10_suppl.571.
By increasing distance between the rectum and prostate, perirectal spacers have been shown to reduce rectal doses during prostate radiotherapy and gastrointestinal toxicity in clinical trials. We aimed to assess rectal and urinary complications in a national sample of individuals receiving prostate radiotherapy with and without a rectal spacer.
__________
Leapman M, Rothen J, Long JB, Kim IE Jr, Mitchell AP, Dinan MA, Gross CP, Ma X. Association between prostate specific membrane antigen imaging and initial treatment for prostate cancer among commercial insurance beneficiaries. JCO Oncol Pract. 2025 Oct 7;21(10 Suppl):577. doi:10.1200/OP.2025.21.10_suppl.577.
Prostate specific membrane antigen positron emission tomography (PSMA-PET) increases the detection of metastatic prostate cancer relative to conventional imaging. To understand whether PSMA-PET is associated with greater use of therapies for metastatic disease we evaluated initial treatment among contemporary commercial insurance beneficiaries undergoing staging evaluation for prostate cancer.
__________
Mitchell AP, Salner A, Palyca P, Farooki A, Persaud S, Chakraborty N, Bhamidipati D, Klimchuk M, Dinan MA, Leapman MS, Lipitz-Snyderman A, Hamid A, Ostroff JS, Morris MJ. Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer. JCO Oncol Pract. 2025 Nov 3:OP2500457. doi: 10.1200/OP-25-00457. Epub ahead of print. PMID: 41183247; PMCID: PMC12614842.
Oncology clinical practice guidelines recommend bone-modifying agents (BMAs) to decrease skeletal-related events for patients with metastatic castration-resistant prostate cancer (mCRPC) and against BMAs to decrease skeletal-related events in metastatic castration-sensitive prostate cancer (mCSPC). Previous studies have identified gaps in guideline-concordant BMA use, but interprovider variation is poorly understood.
__________
Cueto LN, Huang S, Ghali F, Agbafe VC, Ubachukwu TC, Winer EP, Ross JS, Gross CP. Timeliness of completion of NCI cooperative group trials. JCO Oncol Pract. 2025 Oct 7;21(10 Suppl):490. doi:10.1200/OP.2025.21.10_suppl.490.
The study evaluated the timeliness of completion for NCI cooperative group trials initiated between 2011 and 2019, revealing that 50.2% of trials reached their primary outcome within five years, with only 25.6% of phase III trials achieving this milestone.
__________
Kunst N, Long JB, Sprenkle PC, Kim IY, Saperstein L, Rabil M, Ghaffar U, Karnes RJ, Ma X, Gross CP, Wang SY, Leapman MS. Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation. JAMA Netw Open. 2025 Oct 1;8(10):e2539250. doi: 10.1001/jamanetworkopen.2025.39250. PMID: 41134573; PMCID: PMC12552925.
The study evaluates the cost-effectiveness of PSMA-PET for patients with biochemical recurrence of prostate cancer, finding that while it improves disease detection and offers higher quality-adjusted life-years (QALYs), it also incurs significantly higher costs, resulting in an incremental cost-effectiveness ratio (ICER) that exceeds the willingness-to-pay threshold.
__________
Smani S, Lokeshwar SD, Abello A, Kenney PA. Unified approaches to surgery and systemic therapy for renal cell carcinoma. In: Libertino JA, Gee JR, editors. Renal cancer. Cham: Springer; 2025. p. [447-474]. doi:10.1007/978-3-031-97599-8_23.
The research discusses the integration of surgery and systemic therapy to enhance outcomes for renal cell carcinoma (RCC), highlighting the complexity of adjuvant therapy post-nephrectomy and the recent approval of pembrolizumab, which has shown improved survival.
__________
Casilla-Lennon MM, Kenney PA, Wszolek M, Libertino JA. Open partial nephrectomy. In: Libertino JA, Gee JR, editors. Renal cancer. Cham: Springer; 2025. p. [insert pages]. doi: 10.1007/978-3-031-97599-8_13.
Open partial nephrectomy (PN) is a complex surgical procedure aimed at achieving complete tumor removal while preserving kidney function and minimizing complications. The chapter discusses the rationale and indications for PN, emphasizing the importance of reducing renal ischemia and other factors that can lead to postoperative chronic kidney disease. Techniques for performing open PN are also outlined.
__________
Souroujon AA, Gomez-Santamaría OA, Sundaresan V, Leapman M, Casilla-Lennon M. Nutritional modification in prostate cancer: A narrative review of dietary factors in risk and progression. Clin Nutr ESPEN. 2025 Oct;69:1179. doi:10.1016/j.clnesp.2025.07.1091.
We conducted a comprehensive narrative review of over 150 studies, including randomized controlled trials, meta-analyses, and large-scale cohort studies, to evaluate dietary components associated with PCa incidence, progression, and mortality.
###